Navigation Links
Helix BioPharma Corp. Announces Fiscal 2008 Results
Date:10/28/2008

------------------------

(6,977) (5,858) (4,304)

Change in non-cash

working capital (20) (221) 202

------------------------

Operating activities (6,997) (6,079) (4,102)

Financing activities 14,614 6,480 8,808

Investing activities (266) 6,577 (4,428)

Effect of exchange rate

changes on cash and

cash equivalents 327 9 (16)

------------------------

Cash and cash equivalents:

Increase in the year 7,678 6,987 262

Beginning of the year 11,379 4,392 4,130

------------------------

End of the year 19,057 11,379 4,392

========================

Consolidated Balance Sheets (thousand $)

2008 2007

---------------

Current assets:

Cash and cash equivalents 19,057 11,379

Accounts receivable 349 902

Inventory 458 539

Prepaid and other 446 187

20,310 13,007

Non current assets 1,356 1,266

21,666 14,273

2008 2007

---------------

Current liabilities:

Accounts payable 598 565

Accrued liabilities 546 974

1,144 1,539

Shareholders' equity 20,522 12,734

21,666 14,273

The Company's complete 2008 Consolidated Financial Statements, Manageme
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma Closes $11.4 Million Private Placement
2. Helix BioPharma Announces $11.4 Million Private Placement
3. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
4. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
5. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
6. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
7. Helix BioPharma reports Q2 2008 highlights, financial results
8. Helix BioPharma shareholders vote in favour of management
9. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Helix BioPharma announces Q1 2008 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research ( http://www.bccresearch.com ) reveals in its new report, ... MARKETS , the global market for digital polymerase chain ... This is estimated to grow to $490 billion in ... of 28.6%. , New digital PCR technology has created ... broader PCR field. The opportunities presented by this technology ...
(Date:7/11/2014)... - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that ... use as a once-daily adjunctive therapy for the treatment ... not satisfactorily controlled with conventional therapy.  APTIOM TM ... years of age. Epilepsy is one ... Epilepsy Canada, it affects 0.6% of the population and ...
(Date:7/11/2014)... 2014 Cayenne Medical, Inc., a ... the soft tissue reconstruction segment, announced the worldwide ... surgeries involving the shoulder and extremities. The SureLock ... inserter-controlled deployment method. The unique delivery eliminates manual ... pull-out, or anchor displacement (also commonly know as ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2
... SAN FRANCISCO and WASHINGTON , ... Inc., a clinical-stage cancer biotherapeutics company, today reported positive ... the intravenous (IV) administration of JX-594 to patients with ... delivery to solid tumors, cancer-targeted replication and gene expression, ...
... NEW YORK , May 20 /PRNewswire-Asia-FirstCall/ -- ... "Company"), an international,biopharmaceutical company with operations in the U.S. ... of Convertible Redeemable Series C Preferred Stock,(Series C Preferred) ... the conversion of the Series C Preferred, the Company ...
... by Ki H. Chon, PhD, head of the Department ... partnership with Snehraj Merchant of The ScottCare Corporation, makes ... detect incidents of atrial fibrillation (AF), the most common ... methods. The algorithm, utilized in the new ScottCare CardioView ...
Cached Biology Technology:Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously 2Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously 3Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously 4NeoStem Announces Conversion of Convertible Preferred Stock by Principal Shareholder 2NeoStem Announces Conversion of Convertible Preferred Stock by Principal Shareholder 3NeoStem Announces Conversion of Convertible Preferred Stock by Principal Shareholder 4Detection of potentially deadly atrial fibrillation dramatically improved by new algorithm 2Detection of potentially deadly atrial fibrillation dramatically improved by new algorithm 3
(Date:7/11/2014)... Rio de Janeiro, Brazil- In the brains of ... mechanism that allows an electric or chemical signal ... another. Chemical synapses, which are the most abundant ... inhibitory. Synapse formation is crucial for learning, memory, ... and inhibitory synapses critical for brain function. ...
(Date:7/10/2014)... 1, 2014 Smart technology emphasis grows ... and improved security: NXT-ID, Inc. (OTCBB: NXTD), eBay Inc. (NASDAQ: ... ), Apple Inc. (NASDAQ: AAPL ), Visa Inc. ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused ... the second series of 30 second spots on CNBC for ...
(Date:7/10/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ... "Global Gesture Recognition & Touch-Less Sensing (2D, 3D, ... report to their offering ... & Touch-Less Sensing Market to Grow Exponentially. Touch-less ... but the companies were unable to leverage this ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... the building of high speed rail lines in China will ... Professor Rongfang (Rachel) Liu takes the stage at the annual ... the world,s largest gathering in transportation, if not all of ... Liu, an expert in high speed rail lines ...
... mounting concerns over childhood obesity and its associated health ... advertising aimed at children be more effective than the ... a University of Illinois economist, advertising bans do work, ... market would be the most effective policy tool for ...
... beetle dance provides crucial orientation cues: Beetles climb on top of ... The dung beetle dance, performed as the beetle moves away from ... to maintain the desired straight-line departure from the pile, according to ... journal PLoS ONE . The purpose of this ...
Cached Biology News:NJIT high speed rail expert to address DC conference next week 2NJIT high speed rail expert to address DC conference next week 3Study: Quebec ban on fast-food ads reduced consumption of junk food 2Study: Quebec ban on fast-food ads reduced consumption of junk food 3
... Chicken polyclonal to Opsin 1 ( Abpromise ... Antigen: Synthetic peptide: YEDSTHASIFTYT, corresponding to amino ... and synthetic peptide corresponding to amino acids 18/30 ... and used as immunogen. Entrez ...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Request Info...
Myt 1 (N-17)...
Biology Products: